News

Discover the latest news stories, blog posts and publications from Cobra's expert team

Home / News

or

Posts about

Gene Therapy

CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01

Gene Therapy, CombiGene, plasmid dna, CG01, epilepsy

The agreement is part of preparations for GMP production of material for the first clinical study of CG01

Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate

Gene Therapy, CombiGene, plasmid dna, CG01, epilepsy

Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks

Cobra Biologics delivers final plasmids for production of CG01 in CombiGene's epilepsy project

Gene Therapy, CombiGene, plasmid dna, CG01, epilepsy

Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy

Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project CG01 with delivery of first DNA plasmid

Gene Therapy, News, CombiGene, plasmid dna

Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics

Gene Therapy, General, cell therapy, acquisition, Cognate BioServices

This transaction further supports Cognate's mission to meet the needs of the ultimate consumer of its services — the patients with unmet medical needs

Cognate BioServices announces acquisition of Cobra Biologics

Gene Therapy, General, cell therapy, acquisition, Cognate BioServices

Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products aaaaa

CPI Accelerates Gene Therapy Development with Robust Adeno-Associated Virus Purification System in Partnership with Cobra Biologics and GE Healthcare

Viral Vectors, Gene Therapy, Collaboration, CPI, AAV, Innovate, Centre for Process Innovation, GE Healthcare, adeno-associated virus

The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly. CPI has announced the success of its CRD IUK project to develop a scalable, cost-effective purification process for adeno-associated viruses (AAVs), in partnership with Cobra Biologics and GE Healthcare Life Sciences. The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.

CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01

Viral Vectors, Gene Therapy, Collaboration, AAV, CombiGene

Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials (Svensk version nedan)

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

Viral Vectors, Gene Therapy, Innovate UK, Cobra Biologics, adeno-associated virus, Pall Corporation, grant, Cell and Gene Therapy Catapult

Co-winners of the grant, Pall Corporation and the Cell and Gene Therapy Catapult, will work with Cobra Biologics to investigate continuous manufacturing of adeno-associated virus.

Cobra Biologics Celebrates the Queen’s Award for Enterprise in International Trade

Gene Therapy, business, award, General, immunotherapy, Queen's Award, export, international trade

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for advanced therapies. Keele, UK: Cobra Biologics (“Cobra”) a leading international contract development and manufacturing organisation (“CDMO”) were presented with the Queen’s Award for Enterprise in International Trade 2018, by the Lord Lieutenant of Staffordshire on 20 September 2018. The prestigious award is in recognition of Cobra’s commercial success in providing services to its global customer base. Guests attending the event included representatives from Keele

BLOG: Rare Disease Day

Gene Therapy, blog, rare disease day

Rare Disease Day on the 28th February is aimed at raising awareness of the millions of people across the world whose lives are impacted by a rare disease. Rare Disease Day on the 28th February is aimed at raising awareness of the millions of people across the world whose lives are impacted by a rare disease. These are recognised in Europe as a disease that affect less than 1:2000 of the population, but with over 6000 recognised rare diseases this means that in the region of 1:17 people across the world are impact by these types of diseases at some point in their lives.

1 2